In the Boardroom
Refine Search
Biotechnology
In what came as a surprise to most, Gilead Sciences announced today that Norbert Bischofberger has decided to step down from his role as executive vice president, R&D and chief scientific officer, effective at the end of April 2018. He will remain with the company through July. 12 March 2018
Biotechnology
Experienced deal-maker Henrik Stenqvist will take over from retiring Mats-Olof Wallin to become the chief financial officer (CFO) of rare diseases specialist Swedish Orphan Biovitrum, the company has announced. 26 February 2018
Biotechnology
Axovant Sciences today announced that its chief executive Officer David Hung has resigned to pursue other opportunities and has also resigned from the company’s board of directors. 12 February 2018
Biotechnology
Oxford, UK-based biotech Immunocore, the soluble TCR company developing first-in-class biologics that have the potential to transform patient lives, has announced that Dr Eliot Forster has stepped down as chief executive. 12 February 2018
Biotechnology
Just a month after Bo Jesper Hansen was named as chairman of the board of Belgian biotech Ablynx, his resignation has been announced. 7 February 2018
Biotechnology
Following the departure of Christophe Bourdon in December, US drugmaker Alexion Pharmaceuticals has named his replacement in the role of senior vice president and head of Europe/Middle East/Africa/Canada (EMEAC). 30 January 2018
Biotechnology
Belgian biotech firm Ablynx today announced the appointment of Robert Friesen as chief scientific officer (CSO), effective March 1, 2018. 24 January 2018
Biotechnology
Swedish biotech firm Alligator Bioscience has appointed Anu Balendran, as vice president business development. 18 January 2018
Biotechnology
Dr Peter Fellner, who has served as chairman of Belgian biotech firm Ablynx since 2013, has decided to resign from the board with immediate effect. 9 January 2018
Biotechnology
US biotech Neurocrine Biosciences has named an experienced Eli Lilly executive its new chief medical officer after Christopher O'Brien announced that he would be retiring. 8 January 2018
Biotechnology
US biotech firm Array BioPharma has launched a new subsidiary to develop drugs using its ARRY-797 drug program, according to a filing with the US Securities and Exchange Commission (SEC). 30 December 2017
Biotechnology
Clinical-stage US biotech Provectus Biopharmaceuticals has reached a settlement with the US Securities and Exchange Commission (SEC) in connection with investigations relating to two former executives and the company. 13 December 2017
Biotechnology
French biotech company Cellectis has appointed Professor Stéphane Depil to the role of senior vice president R&D and chief medical officer. 5 December 2017
Biotechnology
US biotech major Biogen has appointed Mark Hernon as senior vice president, chief information officer, effective December 4. 4 December 2017
Biotechnology
Alligator Bioscience today announced the expansion of its management team with the appointment of Charlotte Russell as chief medical officer and Peter Ellmark as vice president discovery. 4 December 2017
Biotechnology
The Supervisory Board of Selvita has appointed Edyta Jaworska to the position of a management board member, responsible for the development of its integrated drug discovery services. 30 November 2017
Biotechnology
A series of promotions has been announced at US biopharmaceutical company Nektar Therapeutics. 23 November 2017
Biotechnology
Jeffrey Capello has been named executive vice president and chief financial officer (CFO) of US biotech company Biogen. 21 November 2017
Biotechnology
Canadian clinical-stage immuno-oncology (I-O) company Turnstone Biologics has named Mike Burgess as president of research and development (R&D). 16 November 2017
Biotechnology
Tony de Fougerolles has been named chief executive of privately-held UK biotech Evox Therapeutics. 13 November 2017
Biotechnology
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
Biotechnology
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Biotechnology
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
Biotechnology
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Biotechnology
Turnstone Biologics has announced a major restructuring of its operations, cutting its workforce by approximately 60%. 14 October 2024
Biotechnology
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Biotechnology
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze